Relay Therapeutics, Inc. (RLAY)
18.10
+0.02
(+0.11%)
USD |
NASDAQ |
Nov 13, 16:00
18.10
0.00 (0.00%)
After-Hours: 19:59
Relay Therapeutics Enterprise Value : 3.147B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 3.147B |
| November 11, 2026 | 3.507B |
| November 10, 2026 | 3.555B |
| November 09, 2026 | 3.654B |
| November 06, 2026 | 3.261B |
| November 05, 2026 | 2.910B |
| November 04, 2026 | 3.136B |
| November 03, 2026 | 3.006B |
| November 02, 2026 | 2.971B |
| October 30, 2026 | 3.206B |
| October 29, 2026 | 3.452B |
| October 28, 2026 | 3.500B |
| October 27, 2026 | 3.314B |
| October 26, 2026 | 3.156B |
| October 23, 2026 | 3.169B |
| October 22, 2026 | 3.204B |
| October 21, 2026 | 3.219B |
| October 20, 2026 | 3.228B |
| October 19, 2026 | 2.930B |
| October 16, 2026 | 2.752B |
| October 15, 2026 | 2.976B |
| October 14, 2026 | 2.923B |
| October 13, 2026 | 2.989B |
| October 12, 2026 | 3.125B |
| October 09, 2026 | 3.103B |
| Date | Value |
|---|---|
| October 08, 2026 | 3.000B |
| October 07, 2026 | 3.118B |
| October 06, 2026 | 3.292B |
| October 05, 2026 | 3.435B |
| October 02, 2026 | 3.340B |
| October 01, 2026 | 3.237B |
| September 30, 2026 | 3.140B |
| September 29, 2026 | 3.132B |
| September 28, 2026 | 2.986B |
| September 25, 2026 | 2.937B |
| September 24, 2026 | 2.994B |
| September 23, 2026 | 3.060B |
| September 22, 2026 | 3.348B |
| September 21, 2026 | 3.095B |
| September 18, 2026 | 3.237B |
| September 17, 2026 | 3.313B |
| September 16, 2026 | 3.237B |
| September 15, 2026 | 3.265B |
| September 14, 2026 | 3.285B |
| September 11, 2026 | 3.243B |
| September 10, 2026 | 3.248B |
| September 09, 2026 | 3.198B |
| September 08, 2026 | 3.296B |
| September 04, 2026 | 3.281B |
| September 03, 2026 | 3.274B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 1.484B |
| TG Therapeutics, Inc. | 10.01B |
| Spyre Therapeutics, Inc. | 8.332B |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -81.74M |
| Total Expenses (Quarterly) | 81.74M |
| EPS Diluted (Quarterly) | -0.373 |
| Earnings Yield | -8.34% |
| Normalized Earnings Yield | -8.341 |